Medline gains as investors revisit growth outlook after upbeat conference remarks

Medline Inc. (MDLN) is up 7.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to renewed investor optimism after management struck a constructive tone at a healthcare conference and reiterated a long-term growth framework built on market-share gains, Medline-brand conversion, and automation. The stock may also be benefiting from a rebound after recent weakness, with investors focusing more on revenue momentum than on the company’s previously reduced EBITDA outlook.

Details:

At a mid-September healthcare conference, management described second-quarter demand as strong, highlighted continued market-share gains, and said the company is still targeting about $1 billion of new customer signings annually.

Management said surgical solutions rose in the first half of 2026 and that it had not seen the softness in procedure volumes that some investors were worried about.

The company has also been emphasizing new customer wins and prime-vendor agreements in recent weeks, which can reinforce the view that Medline is still expanding its customer base despite margin pressure.

In August, Medline raised its 2026 organic sales growth outlook to 9.0% to 10.0%, even as it lowered EBITDA guidance because of higher input, freight, and fire-related costs; today’s rally suggests investors may be leaning toward the stronger sales narrative.

Sources:

Medline Investor Relations, SEC, Stock Analysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MDLN Insider Trading Activity

$MDLN insiders have traded $MDLN stock on the open market 21 times in the past 6 months. Of those trades, 1 have been purchases and 20 have been sales.

Here’s a breakdown of recent trading of $MDLN stock by insiders over the last 6 months:

8 HOLDINGS MOZART MANAGER L.L.C. BCP has made 0 purchases and 4 sales selling 33,317,824 shares for an estimated $1,217,349,994.
MOZART ML-2 HOLDCO L.P. BX has made 0 purchases and 4 sales selling 33,317,824 shares for an estimated $1,217,349,994.
& FRIEDMAN CAPITAL PARTNERS X (PARALLEL), L.P. HELLMAN has made 0 purchases and 4 sales selling 31,868,237 shares for an estimated $1,164,385,709.
PRIVATE LTD GIC has made 0 purchases and 6 sales selling 4,438,896 shares for an estimated $158,253,752.
DOUGLAS P GOLWAS (Chief Commercial Officer) has made 0 purchases and 2 sales selling 100,000 shares for an estimated $3,677,115.
JESSI L CORCORAN (Principal Accounting Officer) purchased 5,000 shares for an estimated $170,750

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$MDLN Hedge Fund Activity

We have seen 322 institutional investors add shares of $MDLN stock to their portfolio, and 161 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CARLYLE GROUP INC. removed 28,219,323 shares (-13.1%) from their portfolio in Q2 2026, for an estimated $1,112,970,099
INVESCO LTD. added 17,383,322 shares (+82.9%) to their portfolio in Q2 2026, for an estimated $685,598,219
CAPITAL RESEARCH GLOBAL INVESTORS added 16,802,120 shares (+72.5%) to their portfolio in Q2 2026, for an estimated $662,675,612
H&F CORPORATE INVESTORS X, LTD. removed 15,599,171 shares (-18.0%) from their portfolio in Q2 2026, for an estimated $615,231,304
EGERTON CAPITAL (UK) LLP added 12,105,082 shares (+277.3%) to their portfolio in Q2 2026, for an estimated $477,424,434
FMR LLC added 10,407,002 shares (+28.5%) to their portfolio in Q2 2026, for an estimated $410,452,158
BLACKROCK, INC. added 9,469,927 shares (+56.0%) to their portfolio in Q2 2026, for an estimated $373,493,920

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MDLN Analyst Ratings

Wall Street analysts have issued reports on $MDLN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Tigress Financial issued a "Buy" rating on 05/13/2026

To track analyst ratings and price targets for $MDLN, check out Quiver Quantitative's $MDLN forecast page.

$MDLN Price Targets

Multiple analysts have issued price targets for $MDLN recently. We have seen 7 analysts offer price targets for $MDLN in the last 6 months, with a median target of $54.0.

Here are some recent targets:

Eric Coldwell from Baird set a target price of $45.0 on 06/03/2026
Glen Santangelo from Barclays set a target price of $45.0 on 06/01/2026
Navann Ty from BNP Paribas set a target price of $40.0 on 05/14/2026
Ivan Feinseth from Tigress Financial set a target price of $62.0 on 05/13/2026
David Larsen from BTIG set a target price of $55.0 on 05/07/2026
Lee Hambright from Bernstein set a target price of $54.0 on 05/07/2026
Patrick Donnelly from Citigroup set a target price of $55.0 on 05/07/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.